Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

React to this article
Latest news
Date Title
09:16a SAUDI BASIC : SABIC forms 50:50 JV with Korea s SK Global
09:16a HOCHTIEF : $1.45bn deal signed for Saudi airport upgrade
09:16a OMAGINE : project, worth $2.5bn, takes off in Oman
09:16a AMERICAN AIRLINES : Cargo to develop Middle East reach
09:10a PEUGEOT : Western countries waiting to return to Iranian market
09:10a SONY : PS4, PS3 Again Experiencing PSN Issues
09:04a BUNDESBANK CHIEF WARNS OF GREXIT DAMAGE TO GERMAN BUDGET : Handelsblatt
09:02aDJItalian PM Says Greek Bailout Talks Must Resume After Referendum Result
09:01a Greek Finance Minister says will resign if Greeks vote 'yes'- Bild
09:01a Bundesbank chief warns of Grexit damage to German budget - Handelsblatt
Latest news
Advertisement
Hot News 
NATERA : Nasdaq: NTRA) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
UBISENSE : Hit By Contract Delays, To Restructure Operations
SEAE HLDG : SeaSpine Holdings Corporation Begins Trading on NASDAQ
OUTSOURCERY : New Debt Facilities from Vodafone
STADIUM : Trading In Line With China Facility Relocation On Track
Most Read News
07/04 PROVEXIS : Placing of shares via Primarybid.com
06:04a ADA : OPINION: Robert Ehlert: Idaho health needs attention beyond headlines
02:45a DANA GAS PJS : This disclosure is made pursuant to article 33 of the regulations of the abu dhabi stock exchange as to disclosure and transparency
07/04 IRC PROPERTIES : secures funding for Binangonan real estate venture
07/04 GUARANTY BANK : Innoson Group, GTBank square up over N30b lawsuit
Most recommended articles
09:04a BUNDESBANK CHIEF WARNS OF GREXIT DAMAGE TO GERMAN BUDGET : Handelsblatt
09:02aDJItalian PM Says Greek Bailout Talks Must Resume After Referendum Result
09:01a Greek Finance Minister says will resign if Greeks vote 'yes'- Bild
09:01a Bundesbank chief warns of Grexit damage to German budget - Handelsblatt
08:51a Europe can't count on ECB alone in Greek crisis - French minister